Skip to content

FluoroPharma Medical, Inc.: 10-K filed 2012-03-16

What FluoroPharma Medical, Inc. reported in its annual report filed 2012-03-16 (fiscal FY 2011): 28 published measures, 81 facts as tagged in accession 0001415889-12-000381.

This filing

Form
10-K (annual report)
Filed
2012-03-16
Fiscal period
fiscal FY 2011
Accession
0001415889-12-000381 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All FluoroPharma Medical, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-313,546,395USD
At 2010-12-31113,021USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-313,165,991USD
At 2010-12-31-1,918,162USD
At 2009-12-31-1,062,847USD
At 2008-12-31-2,590,609USD
At 2007-12-31-809,543USD
At 2006-12-31-154,130USD
At 2005-12-31-285,121USD
At 2004-12-31-56,349USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-12-313,265,141USD
At 2010-12-3111,413USD
At 2009-12-311,724USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-3,428,105USD365
2003-06-13 to 2011-12-31-11,896,341USD3124
2010-01-01 to 2010-12-31-954,118USD365
2009-01-01 to 2009-12-31132,005USD365
2008-01-01 to 2008-12-31-2,272,144USD366
2007-01-01 to 2007-12-31-2,354,043USD365
2006-01-01 to 2006-12-31-1,999,214USD365
2005-01-01 to 2005-12-31-687,576USD365
2004-01-01 to 2004-12-31-333,146USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-2,279,996USD365
2003-06-13 to 2011-12-31-7,879,289USD3124
2010-01-01 to 2010-12-31-475,556USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-12-31163,424USD365
2003-06-13 to 2011-12-31372,043USD3124
2010-01-01 to 2010-12-314,755USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-12-315,719,579USD365
2003-06-13 to 2011-12-3111,678,013USD3124
2010-01-01 to 2010-12-31490,000USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-185,855USD365
2003-06-13 to 2011-12-31-533,583USD3124
2010-01-01 to 2010-12-31-4,755USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-12-31-12,873,729USD
At 2010-12-31-8,468,236USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2011-01-01 to 2011-12-3117,732,273shares365
2010-01-01 to 2010-12-3112,705,038shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-0.25USD/shares365
2010-01-01 to 2010-12-31-0.08USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-0.25USD/shares365
2010-01-01 to 2010-12-31-0.08USD/shares365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-12-31169,808USD
At 2010-12-3129,952USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,736,917USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-313,315,432USD
At 2010-12-3127,179USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-01-01 to 2011-12-31113,192USD365
2003-06-13 to 2011-12-31316,326USD3124
2010-01-01 to 2010-12-3153,223USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-12-31380,404USD
At 2010-12-312,031,183USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-12-31341,172USD
At 2010-12-31842,357USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2011-12-3161,155USD
At 2010-12-3155,890USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-01-01 to 2011-12-313,439,802USD365
2003-06-13 to 2011-12-3112,995,809USD3124
2010-01-01 to 2010-12-31892,549USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-01-01 to 2011-12-31640,730USD365
2003-06-13 to 2011-12-314,643,777USD3124
2010-01-01 to 2010-12-3144,504USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-12-3122,310,894shares
At 2010-12-3112,705,038shares

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-4,405,493USD365
2003-06-13 to 2011-12-31-12,873,729USD3124
2010-01-01 to 2010-12-31-954,118USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-312,075,100USD365
2003-06-13 to 2011-12-3149,807USD3124
2010-01-01 to 2010-12-31441,402USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-01-01 to 2011-12-3123,569USD365
2003-06-13 to 2011-12-31131,084USD3124
2010-01-01 to 2010-12-3125,450USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-01-01 to 2011-12-3111,697USD365
2003-06-13 to 2011-12-311,099,468USD3124
2010-01-01 to 2010-12-31-61,569USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2003-06-13 to 2011-12-3150,000USD3124
2010-01-01 to 2010-12-3150,000USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-318,211USD365
2003-06-13 to 2011-12-31706,119USD3124
2010-01-01 to 2010-12-3156,568USD365

Inspect the source

Entity
FluoroPharma Medical, Inc. / CIK 0001402785
Captured
SEC response SHA-256
4d77d986a03178d60883d667e91c227ed829415c26872c73ee7ae0df9851ff14

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001402785.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))